Pfizer Beats Street Reporting Q4 & Full-Year 2017 Earnings

Pfizer (PFE) reported earnings on 1/30/2018 of $0.62/share firmly beating estimates of $0.583 per share.

Pfizer’s abbreviated notes are as follows:

  • Full-Year 2017 Revenues of $52.5 Billion, Comparable with Full-Year 2016 Operationally; Excluding Impact of February 2017 Divestiture of Hospira Infusion Systems (HIS), Revenues Increased 2% Operationally
  • Fourth-Quarter 2017 Revenues of $13.7 Billion, Comparable with Fourth-Quarter 2016 Operationally; Excluding Impact of February 2017 Divestiture of HIS, Revenues Increased 2% Operationally
  • Full-Year 2017 Reported Diluted EPS(1) of $3.52, Adjusted Diluted EPS(2) of $2.65; Fourth-Quarter 2017 Reported Diluted EPS(1) of $2.02, Adjusted Diluted EPS(2) of $0.62
  • Provides 2018 Financial Guidance, Including Revenues of $53.5 to $55.5 Billion, Adjusted Diluted EPS(2) of $2.90 to $3.00 and Adjusted Effective Tax Rate(2) of Approximately 17.0%
  • 2018 Guidance Midpoints Imply Revenue Growth of 4% and Adjusted Diluted EPS(2) Growth of 11% Anticipates Repatriation Tax Liability of Approximately $15 Billion, Payable to the U.S. Treasury

 

Ian Read, Chairman and Chief Executive Officer, stated, “Pfizer had a strong year in 2017, delivering solid financial results, advancing several significant pipeline programs and enhancing shareholder value with prudent capital allocation decisions. Regarding our revenue performance in 2017, Pfizer Innovative Health was driven by continued strength from several anchor brands, including Ibrance, Eliquis and Xeljanz — all of which currently have market-leading positions with many years of patent protection remaining. Pfizer Essential Health generated strong operational revenue growth in emerging markets and in our Biosimilars portfolio but was negatively impacted by the HIS divestiture, the expected impact of product losses of exclusivity and legacy Hospira product shortages in the U.S.

“In 2017, we received ten approvals from the FDA, significantly more than Pfizer has achieved in any year in the past decade. Building on these achievements, during 2018 we look forward to important regulatory decisions and clinical data readouts across our pipeline that will drive the next wave of innovation at Pfizer.

“I believe our capital allocation decisions in 2017 enhanced shareholder value. In addition to investing in our business, we also returned $12.7 billion directly to shareholders through a combination of dividends and share repurchases and we decided to explore potential strategic alternatives for our Consumer Healthcare business. We remain on track to make this decision, which could include everything from a full or partial separation to ultimately deciding to retain the business, during 2018.

“I believe our current management and business structure, the tireless dedication of our colleagues and the strong culture we have nurtured position Pfizer especially well for continued success,” Mr. Read concluded.

Frank D’Amelio, Executive Vice President, Business Operations and Chief Financial Officer, stated, “Overall, I am pleased with our 2017 financial performance. Despite absorbing a $2.1 billion impact from products that recently lost marketing exclusivity, we were still able to achieve 1% operational revenue growth in 2017 after excluding the net impact of acquisitions and divestitures completed in 2016 and 2017. We also delivered Adjusted diluted EPS(2) growth of 11% in 2017, primarily reflecting a lower effective tax rate due to tax reform, strong performance of key products, continued success in managing our operating expenses and the net impact of our share repurchases.

“Our 2018 financial guidance at the midpoint of our ranges implies revenue growth of 4% and Adjusted diluted EPS(2) growth of 11% compared to 2017 results, which absorbs an anticipated $2.0 billion revenue headwind due to products that recently lost marketing exclusivity. Our effective tax rate on Adjusted income(2) is expected to be approximately 17.0% in 2018, significantly lower than the approximately 23.0% that we previously anticipated for full-year 2017, prior to the enactment of tax reform. Notably, our guidance for Adjusted diluted EPS(2) anticipates share repurchases totaling $5.0 billion in 2018, which is expected to be offset by approximately half due to dilution related to share-based employee compensation programs.

“Finally, regarding tax reform, I am pleased that the aspects of most importance to us were addressed in the new tax code, strengthening our ability to make capital allocation decisions that maximize patient benefit and enhance shareholder value. In addition to an anticipated effective tax rate on Adjusted income(2) in 2018 that is meaningfully lower than in prior years, Pfizer anticipates a repatriation tax liability of approximately $15 billion payable to the U.S. Treasury over eight years as a result of the passage of the TCJA,” Mr. D’Amelio concluded.

To learn more about Pfizer (PFE) and to track its progress please visit the Vista Partners Pfizer Coverage Page.

s21.q4cdn.com

Read Full Article



Atossa Genetics (ATOS) to Host Conference Call Feb 1 to Present Additional Findings From Breast Cancer Program

Vista Partners recently (01-22-18) published a Report on Seattle based Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage drug company developing novel, proprietary therapeutics and delivery methods for breast cancer and other breast conditions. They believe their innovative therapies and delivery methods can transform breast cancer treatment.
DOWNLOAD the FREE Report at http://www.vistapglobal.com/vp-coverage/atossa-genetics-inc-atos/.
Today,  Atossa Genetics Inc. announced it will host a conference call on Thursday, February 1, 2018, at 4:30 pm EST to discuss additional findings from its Phase 1 study of Atossa’s proprietary oral Endoxifen. Endoxifen is an active metabolite of the FDA-approved drug tamoxifen, which is currently used to treat breast cancer and for breast cancer prevention in high-risk patients.
The objectives of this double-blinded, placebo-controlled, Phase 1 study of 48 healthy female subjects were to assess the pharmacokinetics of proprietary formulations of both oral and topical Endoxifen dosage forms as single (oral) and repeat (oral and topical) doses, as well as to assess safety and tolerability. Preliminary results from the study, which were announced on September 14, 2017, and October 25, 2017, showed that all objectives of the study were successfully met:  there were no clinically significant safety signals and no clinically significant adverse events and both the oral and topical Endoxifen were well tolerated.  In the topical arm of the study, low but measurable Endoxifen levels were detected in the blood in a dose-dependent fashion. In the oral arm of the study, participants exhibited dose-dependent Endoxifen levels that met or exceeded the published therapeutic level. Additional findings from the oral arm of the Phase 1 study will be announced during the conference call on February 1, 2018.
Due to expected high call attendance, participants are asked to pre-register for the call through the following link: http://dpregister.com/10116753. Please note that registered participants will receive their dial-in number upon registration and will dial directly into the call without delay. Those without internet access or who are unable to pre-register may dial in by calling: 1-844-824-3830 (domestic), 1-412-317-5140 (international) and Canada Toll-Free: 1-855-669-9657. Callers should ask to be joined into the Atossa Genetics call.
The conference call will also be available through a live webcast at www.atossagenetics.com. Details for the webcast may be found on the Company’s IR events page at http://ir.atossagenetics.com/ir-calendar.
Management will answer pre-submitted questions gathered prior to the conference call in the Question and Answer period of the call. Interested parties may submit questions for management’s consideration prior to the call by submitting them in writing to Atossa Genetics’ Investor Relations at scottg@coreir.com.
A replay of the call will be available approximately one hour after the end of the call through March 1, 2018. The replay can be accessed via Atossa’s website or by dialing 877-344-7529 (domestic) or 412-317-0088 (international) or Canada Toll-Free at 855-669-9658. The replay access code is 10116753.

To learn more about Atossa Genetics (ATOS) and to track its ongoing progress, please visit the Vista Partners Atossa Genetics Coverage Page.

Vista Partners publishes a Weekly Market Update. Each issue is written by Managing Director, John Heerdink and speaks to the activities of the market, influencers and specific featured stories from Vista’s Coverage Universe that spans the Dow 30 and Select Emerging Growth Companies.

Each weekly update issue is sent out via email directly to the thousands of investors around the world that have elected to be updated each week. Please “Join us” to Stay Informed! and to Stay Competitive!

It’s FREE & EASY to sign up.

Atossa Genetics to Host Conference Call to Present Additional Findings from its Phase 1 Study of Oral Endoxifen Thursday February 1, 2018 at 4:30 pm EST

SEATTLE, Jan. 31, 2018– Atossa Genetics Inc., a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, announced today …..

finance.yahoo.com

Read Full Article



Special Vista Partners Update: Atossa Genetics Receives Additional Sell Side Support & Coverage – Shares Surge

Seattle based Atossa Genetics Inc. (NASDAQ: ATOS) is a clinical-stage drug company developing novel, proprietary therapeutics and delivery methods for breast cancer and other breast conditions. They believe their innovative therapies and delivery methods can transform breast cancer treatment.

Early Friday morning shares of Atossa Genetics surged almost 40% and are currently up ~25% with 13,560,000 having traded. The average trading volume is 2,180,000 shares per day.

This week Atossa Genetics received additional support and sponsorship from both Vista Partners LLC and Maxim Group as both firms published favorable reports. Maxim Group initiated coverage with a “buy” & set a 12-month price target of $2/share.

During the fourth-quarter 2017, Atossa Genetics announced that they have started a new program to deliver CAR-T cells into the ducts of the breast for the potential targeted treatment of breast cancer. CAR-T has been the subject of much attention recently. In October 2017, pioneer CAR-T company Kite Pharma was acquired for ~$12B billion by Gilead (GILD). This week Celgene (CELG) announced that they are acquiring Juno Therapeutics, Inc. (JUNO) for approximately $9 billion.

To learn more please DOWNLOAD the Vista Partners FREE Report at http://www.vistapglobal.com/vp-coverage/atossa-genetics-inc-atos/.

 

Stay Informed! Stay Competitive!

Please visit Vista Partners website daily to discover more!




3 FREE Biotech/Healthcare Research Reports: Atossa Genetics Inc. (ATOS), Johnson & Johnson, Inc. (JNJ), & Pfizer Inc. (PFE)

All three reports are available for FREE at the Vista Partners Coverage Page.

Seattle based Atossa Genetics Inc. (NASDAQ: ATOS) is a clinical-stage drug company developing novel, proprietary therapeutics and delivery methods for breast cancer and other breast conditions. They believe their innovative therapies and delivery methods can transform breast cancer treatment.

DOWNLOAD the FREE Report at http://www.vistapglobal.com/vp-coverage/atossa-genetics-inc-atos/.

Dow 30 component Johnson & Johnson, Inc. (JNJ) is an investment holding company with interests in healthcare products. It engages in research and development, manufacture and sale of personal care hygienic products, pharmaceuticals and surgical equipment.

DOWNLOAD the FREE Report at http://www.vistapglobal.com/vp-coverage/johnson-johnson/.

Dow 30 component Pfizer, Inc. (PFE) discovers, develops, manufactures, and sells healthcare products worldwide.

DOWNLOAD the FREE Report at http://www.vistapglobal.com/vp-coverage/pfizer-2/.

Vista Partners offers a wealth of mixed-media resources on the Dow 30 & Select Emerging Growth Companies. Visit www.vistapglobal.com/signup to stay informed with FREE email updates.

About VISTA PARTNERS

Founded in 2005, Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

We encourage readers to view a complete list of disclaimers and disclosures on the Vista Partners website at VistaPGlobal.com/disclaimer.




Merck Receives FDA Approval With First PARP Inhibitor in Metastic Breast Cancer

In July 2017, AstraZeneca and Merck (NYSE: MRK) (known as MSD outside the United States and Canada) announced a global strategic oncology collaboration to co-develop and co-commercialize LYNPARZA, the world’s first PARP inhibitor, and potential new medicine selumetinib, a MEK inhibitor, for multiple cancer types. The collaboration is based on increasing evidence that PARP and MEK inhibitors can be combined with PD-L1/PD-1 inhibitors for a range of tumor types. Working together, the companies will jointly develop LYNPARZA and selumetinib in combination with other potential new medicines and as a monotherapy. Independently, the companies will develop LYNPARZA and selumetinib in combination with their respective PD-L1 and PD-1 medicines.

Recently, the U.S. Food and Drug Administration (FDA) approved LYNPARZA® (olaparib) for use in patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor positive (HR+) breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Patients are selected for therapy based on an FDA-approved companion diagnostic from Myriad Genetics.

Dave Fredrickson, executive vice president, head of the oncology business unit, AstraZeneca, said, “This new approval for LYNPARZA makes it the first and only PARP inhibitor approved in metastatic breast cancer, and the only PARP inhibitor approved outside of ovarian cancer. This is significant for breast cancer patients, as the identification of BRCA status, in addition to hormone receptor and HER2 status, becomes a potentially critical step in the management of their disease.”

The approval was based on data from the randomized, open-label, phase 3 OlympiAD trial, which investigated LYNPARZA (olaparib) versus physician’s choice of chemotherapy (capecitabine, eribulin or vinorelbine). In the trial, LYNPARZA significantly prolonged progression-free survival (PFS) compared with chemotherapy, and reduced the risk of disease progression or death by 42 percent (HR 0.58; 95% CI 0.43-0.80; P=0.0009 median 7.0 vs 4.2 months). Patients with measurable disease taking LYNPARZA (n=167) experienced an objective response rate of 52 percent (95% CI 44-60), double the response rate for those in the chemotherapy arm (n=66), which was 23 percent (95% CI 13-35). Additionally, patients experienced a confirmed complete response rate of 7.8 percent for LYNPARZA compared to 1.5 percent for the chemotherapy arm. The data from the OlympiAD trial can be found in the June 2017 issue of the New England Journal of Medicine.

“Patients diagnosed with BRCA-related metastatic breast cancer are often younger than other breast cancer patients, and their disease is often much more aggressive and difficult to treat,” said Dr. Susan M. Domchek, executive director of the Basser Center for BRCA at the Abramson Cancer Center of the University of Pennsylvania, and national leader on the OlympiAD trials. “While there is currently no cure for metastatic breast cancer, today’s approval offers a new, targeted option that may help to delay disease progression for these patients.”

To learn more about Merck (NYSE: MRK) and to track its ongoing progress please visit the Vista Partners Merck (MRK) Coverage Page found within the Featured Coverage Section at Vista Partners.

If you find the above story interesting,  you should visit the Vista Partners’ Atossa Genetics (ATOS) page to discover the exciting developmental work they are conducting i order to brjng forth treatments for breast cancer!

Stay Informed! Stay Competitive! It’s FREE & EASY to sign up and receive updates from Vista Partners.

U.S. FDA Approves LYNPARZA® (olaparib) in Germline BRCA-Mutated Metastatic Breast Cancer

AstraZeneca and Merck , known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved LYNPARZA® for use in patients with deleterious or suspected deleterious germline BRCA-mutated , human epidermal growth factor receptor 2 -negative metastatic..

finance.yahoo.com

Read Full Article



Johnson & Johnson Releases Q1 2018 Dividends

Johnson & Johnson (JNJ) is a worldwide healthcare focused company that embraces research and science so that it can provide customers with innovative ideas, products and services.

The Board of Directors of Johnson & Johnson declared a cash dividend of $0.84 per common stock share for the first quarter of 2018. The dividend will be payable March 13, 2018 to all shareholders recorded at the close of business on February 27, 2018.

To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.

Johnson & Johnson Announces Quarterly Dividend for First Quarter 2018

NEW BRUNSWICK, N.J., Jan. 2, 2018 /PRNewswire/ — Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2018 of $0.84 per share on the company’s common stock. The dividend is payable on March 13, 2018 to shareholders of record at the close of business on February …..

www.investor.jnj.com

Read Full Article



It’s Almost Time for San Francisco’s J.P. Morgan Healthcare Conference Week!

J.P. Morgan (NYSE: JMP) launched Wall Street’s premier investor conference focused exclusively on companies defining the healthcare industry 35 Years ago. Today, the J.P. Morgan Healthcare Conference hosts the largest and most informative healthcare investment symposium in the industry. In 2018, J.P. Morgan expects more than 400 companies to deliver presentations to more than 8,000 attendees,  but as impressive as these numbers are they fail in comparison to the much greater number of companies, investors, conferences, partnership meetings & night events that are participating, attending and being held during this same week. Some estimate that nearly 60,000 come into the town to capitalize on and around this event. The event next week is on January 8 – 11, 2018 at the Westin St. Francis in San Francisco’s Union Square. All J.P. Morgan conferences are by invitation only. Invitations are non-transferable.

I have been attending J.P. Morgan Conference Week activities since 1999 and again will be meeting with over 30 companies including a wide range of biotech, med-tech and pharmaceutical companies from private entities to multi-billion dollar public companies in order to further identify trends and seek to capitalize on the growth. It will be exhausting but well worth it.

Specifically, I will further be seeking to gain greater insight on 5 companies that I cover at Vista Partners that include: Breast cancer-focused biotech firm Atossa Genetics (ATOS), Short-term insurance provider Health Insurance Innovations (HIIQ), Pharmaceutical Giants Johnson & Johnson (JNJ), Merck (MRK), & Pfizer (PFE). Please see our Coverage Pages for all and to learn more. Any thoughts, ideas or other companies that we should meet with next week please forward introductions to inquiries@vistapglobal.com.

 




“Is It Time to Toast?” See Vista Partners Weekly Market Update 12-30-17

Vista Partners has published  “Is It Time to Toast?” Vista Partners Weekly Market Update 12-30-17 and is accessible on our Newsletters Page. Each issue is written by Managing Director, John Heerdink and speaks to the activities of the market, influencers and specific featured stories from Vista’s Coverage Universe that spans the Dow 30 and Select Emerging Growth Companies.

Each weekly update issue is sent out via email directly to the thousands of investors around the world that have elected to be updated each week. Please “Join us” Today!

Stay Informed! Stay Competitive! It’s FREE & EASY to sign up.

Have a great weekend and a Happy 2018!




CEO of Novartis AG Joseph Jiminez Joins P&G Board of Directors

The Procter & Gamble Company (PG), a Dow 30 component, supplies branded consumer packaged goods to consumers across the globe.

Recently, Joseph Jiminez, the Chief Executive Officer of Novartis AG, was appointed by The Procter & Gamble Company to its Board of Directors, effective March 1, 2018. In his role as Chief Executive Officer of Novartis, Jiminez managed the company’s diversified healthcare portfolio and helped reshape the company through a series of complex transactions in 2015.

Jiminez also currently serves on the Board of General Motors Company and has served on the Boards of several other companies.

“Joe has a distinguished track record of success in healthcare, consumer products, and international businesses. We will deeply benefit from Joe’s experience, expertise, and leadership as we continue to transform P&G.” -David S. Taylor, P&G’s Chairman, President, and Chief Executive Officer

To learn more about Procter & Gamble (PG) and to continue to track its progress please visit the Vista Partners Procter & Gamble Coverage Page.

P&G Appoints Joseph Jimenez of Novartis to Board of Directors | P&G News | Events, Multimedia, Public Relations

CINCINNATI–(BUSINESS WIRE)–The Procter & Gamble Company (NYSE:PG) today announced that it has appointed Joseph Jimenez, Chief Executive Officer of Novartis AG, to its Board of Directors, effective March 1, 2018…

news.pg.com

Read Full Article



Breast Cancer Focused Biotech Atossa Genetics Issues Letter to Stockholders

Dr. Steven C. Quay, President & CEO of Seattle, WA biotech firm Atossa Genetics, issued the following letter to stockholders on December 28th, 2017 highlighting the key accomplishments to date and outlining the milestones for 2018.

Dear Valued Stockholders:

Over the past two years, we have transformed Atossa into a pure play pharmaceutical company focused on the development of novel therapeutics and delivery methods aimed at both treating breast cancer as well as preventing breast cancer. We now have a remarkable opportunity to transform the field of breast cancer and substantially reduce the incidence of this deadly disease.

The current standard of care for most breast cancer patients is a 5-10 year regimen of an FDA-approved drug called Tamoxifen. Unfortunately, not all patients benefit from Tamoxifen and it can have serious side effects. For these reasons, we are developing a new drug called Endoxifen, which is the most active metabolite of Tamoxifen. We are also developing our proprietary intraductal microcatheters with the potential ability to deliver drugs and Chimeric Antigen Receptor Therapy, or CAR-T, cells directly to the site of breast cancer.

Clinical Trial Achievements. Over the past two years we have been developing two proprietary formulations of Endoxifen: oral Endoxifen for the more than one million breast cancer survivors and topical Endoxifen as a potential treatment for a conditions called mammographic breast density (or MBD). There is no FDA-approved treatment for MBD, which affects more than ten million women in the U.S. It is well accepted that MBD increases the risk of breast cancer, which is why 30 states now require that a finding of MBD be reported to the patient, physician or both. It is believed that not only does MBD make mammography less effective because MBD can hide cancerous tumors, but also the tissue itself may be more prone to develop cancer. Over the past year, we secured a manufacturer for Endoxifen, retained a clinical research organization for a Phase 1 study and completed this study in the last quarter of 2017.

Preliminary results of the Phase 1 study show that both arms of the study (oral and topical) were fully and successfully completed: there were no clinically significant safety signals and no clinically significant adverse events and both the oral and topical Endoxifen were well tolerated. In the topical arm of the study, low but measurable Endoxifen levels were detected in the blood in a dose-dependent fashion. In the oral arm of the study, participants exhibited dose-dependent Endoxifen levels that met or exceeded the published therapeutic level.

These promising Phase 1 results have paved the way for our upcoming Phase 2 studies, which are planned to open in the first quarter of 2018. We are developing our proprietary topical Endoxifen for the treatment of women with MBD which will be conducted by Stockholm South General Hospital in Sweden. We are also planning a Phase 2 study using our proprietary oral Endoxifen to treat patients who are not responding to Tamoxifen. That study should also open in the first quarter of 2018.

We have started a new program to deliver CAR-T cells into the ducts of the breast for the potential targeted treatment of breast cancer. This is a novel approach using our proprietary intraductal microcatheter technology for the potential transpapillary, or “TRAP,” delivery of T-cells that have been genetically modified to attack breast cancer cells. We believe this method has several potential advantages including the reduction of toxicity by limiting systemic exposure of the T-cells; improved efficacy by placing the T-cells in direct contact with the target ductal epithelial cells that are undergoing malignant transformation; and, lymphatic migration of the CAR-T cells potentially extending their cytotoxic actions into the regional lymph system, which could limit tumor cell dissemination. This approach is in the R&D stage and is currently not FDA approved. In 2018 we intend to commence studies that will help demonstrate safety and efficacy of this novel approach. We are also using our intraductal microcatheters in a Phase 2 study at Montefiore Medical Center in New York where we are targeting the delivery of Fulvestrant to the site of early stage breast cancer and ductal carcinoma in situ. That study is ongoing.

Capital Raising Achievements. In 2017 we made significant improvements to our balance sheet by raising approximately $12 million in capital, which strengthened our balance sheet and improved our stockholder base with the addition of institutional biotech-focused investors. We now have sufficient capital recourses to execute on our upcoming Endoxifen Phase 2 study of MBD and our upcoming Endoxifen Phase 2 study of “refractory” patients who are not responding to Tamoxifen.

Market Opportunities. We are developing our products for large market opportunities. A study conducted by Defined Health, a leading market research firm, estimates that the potential market for Endoxifen exceeds $1 billion in annual sales and the potential market for our intraductal microcatheters to delivery therapeutics exceeds $800 million as a treatment and replacement for surgery.

CAR-T has been the subject of much attention recently. In October 2017, pioneer CAR-T company Kite Pharma was acquired for $11.9 billion by Gilead and in August 2017 Novartis received the first FDA approval in the CAR-T field for Kymriah for the treatment of B-cell Acute Lymphoblastic Leukemia. Other companies in the clinical-stage in the field of CAR-T include Blue Bird Corporation, and Juno Therapeutics, which trades on Nasdaq with a multi-billion dollar market capitalization.

2018 Milestones. We are now well positioned to execute our strategies in 2018, which include the following potential milestones

First quarter of 2018 – commencing the Phase 2 Study of topical Endoxifen to treat MBD at Stockholm South General Hospital in Sweden (which we plan to complete in 2018).
First quarter of 2018 – commencing the Phase 2 Study of oral Endoxifen to treat patients who are not responding to Tamoxifen (which we plan to complete in 2018).
Second half of 2018 – commencing one or more studies administering TRAP CAR-T with our microcatheters.
Throughout 2018 – continuing our Phase 2 study administering Fulvestrant with our microcatheters.
Breast Cancer Statistics. The American Cancer Society (ACS) estimates that approximately 250,000 women will be diagnosed with breast cancer in the United States this year and that approximately 40,000 will die from the disease. It is the second leading cause of cancer death in American women. Although about 100 times less common than women, breast cancer also affects men. The ACS estimates that the lifetime risk of men getting breast cancer is about 1 in 1,000; 2,470 new cases of invasive breast cancer will be diagnosed; and 460 men will die from breast cancer in 2017.

We look forward to reporting our progress on these priorities throughout the year and we thank you for your continued support of Atossa.

Sincerely,

Dr. Steven C. Quay, MD, Ph.D.
President and Chief Executive Officer

To learn more about Atossa Genetics (ATOS) and to track its ongoing progress, please visit the Vista Partners Atossa Genetics Coverage Page.

Vista Partners publishes a Weekly Market Update. Each issue is written by Managing Director, John Heerdink and speaks to the activities of the market, influencers and specific featured stories from Vista’s Coverage Universe that spans the Dow 30 and Select Emerging Growth Companies.

Each weekly update issue is sent out via email directly to the thousands of investors around the world that have elected to be updated each week. Please “Join us” to Stay Informed! and to Stay Competitive!

It’s FREE & EASY to sign up.

Atossa Genetics President and CEO Issues Letter to Stockholders Highlighting Key Accomplishments and Outlines Milestones for 2018

SEATTLE, Dec. 28, 2017– Atossa Genetics Inc. today announced it has issued the following letter by Dr. Steven C. Quay, President and CEO, to Atossa stockholders:. Over the past two years, we have transformed …..

finance.yahoo.com

Read Full Article